Evidence map›Paper›PMID 41180011›Full record

ArticleNAR cancer2025

Brain tumor classification from FFPE samples using nanopore methylation sequencing.

Galina Feinberg-Gorenshtein, Assaf Grunwald, Carlo Vermeulen, Nurit Gal Mark, Elena Shinderman-Maman, Adva Levy-Barda, Keren Shichrur, Michal Hameiri-Grossman, Orli Michaeli, Shira Amar and 13 more

Abstract read
In one paragraph

Article in NAR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Galina Feinberg-GorenshteinThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.ORCID 0009-0009-4457-3445
Assaf GrunwaldDepartment of Physical Chemistry, School of Chemistry, Tel Aviv University, P.O. Box 39040, Tel Aviv, Israel.
Carlo VermeulenCenter for Molecular Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
Nurit Gal MarkThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Elena Shinderman-MamanThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Adva Levy-BardaBiobank, Department of Pathology, Rabin Medical Center (Beilinson Hospital), Attn: Biobank, 39 Ze'ev Jabotinsky Street, Petah Tikva 4941492, Israel.
Keren ShichrurThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Michal Hameiri-GrossmanThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Orli MichaeliThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Shira AmarThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Suzanna FichmanDepartment of Pathology, Beilinson Hospital Institute of Pathology, 39 Ze'ev Jabotinsky Street, Petah Tikva 4941492, Israel.
Abraham NatanDepartment of Pathology, Beilinson Hospital Institute of Pathology, 39 Ze'ev Jabotinsky Street, Petah Tikva 4941492, Israel.
Tali SiegalTel Aviv University, Gray Faculty of Medical and Health Sciences, P.O. Box 39040, Tel Aviv, Israel.
Shlomit Yust-KatzTel Aviv University, Gray Faculty of Medical and Health Sciences, P.O. Box 39040, Tel Aviv, Israel.
Hanna WeissDepartment of Pathology, Beilinson Hospital Institute of Pathology, 39 Ze'ev Jabotinsky Street, Petah Tikva 4941492, Israel.
Osnat KonenThe Institute of Imaging, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Amir KershenovichDivision of Pediatric Neurosurgery, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Andrew A KannerDepartment of Pathology, Beilinson Hospital Institute of Pathology, 39 Ze'ev Jabotinsky Street, Petah Tikva 4941492, Israel.
Jeroen de RidderCenter for Molecular Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
Helen ToledanoThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Shai IzraeliThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Yehudit BirgerThe Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, P.O. Box 559, Petach Tikva, Israel.
Yuval EbensteinDepartment of Physical Chemistry, School of Chemistry, Tel Aviv University, P.O. Box 39040, Tel Aviv, Israel.

Funding

Nanopore based profiling of epigenetic stateR01HG009190 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI TIMP, WINSTON GEORGE · 2017 to 2024
$4.8M
NHGRI NIH HHS R01 HG009190
6 · The paper itself

Abstract

Oxford Nanopore Technology (ONT)-based methylation sequencing is emerging as a powerful approach for the rapid and accurate classification of brain tumors, an essential component of precision oncology. However, its broader clinical adoption has been limited by reliance on fresh-frozen (FF) tissue, whereas the vast majority of clinical specimens are formalin-fixed paraffin-embedded (FFPE). In this study, we address this limitation by evaluating the effects of FFPE processing on DNA methylation profiles and introducing a validated protocol for ONT-based classification using DNA extracted directly from pathology-marked regions on stained FFPE slides. This approach enables the targeted selection of tumor-rich areas following histological assessment, thereby improving DNA input quality and tumor content. We demonstrate that even small, low-input samples (≥25 ng) can be successfully classified using this method, with high concordance to final integrated neuropathological diagnoses. Our results show that, despite modest methylation loss associated with formalin fixation, classification performance remains robust. Notably, we identify a correlation between methylation degradation and fixation time, supporting a recommendation to limit formalin exposure to ≤3-4 days when possible. By enabling accurate methylation-based tumor classification from routinely processed, stained FFPE tissue, our protocol integrates seamlessly into existing clinical workflows. This expands the accessibility of ONT-based diagnostics and supports informed, timely treatment decisions-even in cases with minimal tissue availability or urgent clinical need.

Indexed as

Brain NeoplasmsDNA MethylationNanopore SequencingFormaldehydeHumansParaffin EmbeddingTissue FixationFormaldehyde

Identifiers

PMID41180011
PMCPMC12574666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.